EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Promising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer

Prabhjot Kaur, Santosh Kumar Singh iD, Manoj K Mishra iD, Shailesh Singh, Rajesh Singh iD

Cancers · 12.06.2024 · 16 (12) · 2205

DOI: 10.3390/cancers16122205 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 12.06.2024. Verfasst von Prabhjot Kaur und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, Atlanta, GA 30310, USA. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 126 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, the National Cancer Institute, the American Cancer Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Non-small cell lung cancer (NSCLC) presents a complex and diverse disease, exhibiting variations at individuals’ cellular and histological levels. This complexity gives rise to different subtypes and genetic mutations, posing challenges for accurate diagnosis and effective treatment. Nevertheless, continuous progress in medical research and therapies is continually shaping the landscape of NSCLC diagnosis and management. The treatment of NSCLC has undergone significant advancements in recent years, especially with the emergence of targeted therapies that have shown remarkable efficacy in patients with actionable mutations. This has ushered in the era of personalized medicine in NSCLC treatment, with improvements in molecular and immunohistochemical techniques contributing to enhanced progression-free survival. This review focuses on the latest progress, challenges, and future directions in developing targeted therapies for NSCLC, including tyrosine kinase inhibitors (TKIs), DNA-damaging agents, immunotherapy regimens, natural drug therapy, and nanobodies. Furthermore, recent randomized studies have demonstrated enhanced overall survival in patients receiving different targeted and natural drug therapies.

Schlagwörter

Stichwörter der Autor:innen

PARP inhibitorsPDL-1clinical trialsimmune checkpoint inhibitorsnanobodiesnatural drug therapytyrosine kinase inhibitors

Autor:innen und Institutionen

  • Department of Microbiology, Biochemistry, and Immunology, Morehouse School of Medicine, Atlanta, GA 30310, USA.
  • Cancer Biology Research and Training, Department of Biological Sciences, Alabama State University, Montgomery, AL 36014, USA.
  • Cancer Health Equity Institute, Morehouse School of Medicine, Atlanta, GA 30310, USA.

ORCID-Profile: Santosh Kumar Singh, Manoj K Mishra, Rajesh Singh

Förderung

  • NCI NIH HHS
  • the National Cancer Institute
  • the American Cancer Society
  • the Department of Defense
  • the National Institutes of Health
  • National Institutes of Health
  • National Cancer Institute
  • American Cancer Society

Zitieren

APA

Kaur, P., Singh, S. K., Mishra, M. K., Singh, S., & Singh, R. (2024). Promising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer. Cancers, 16(12), 2205. https://doi.org/10.3390/cancers16122205

Vancouver

Kaur P, Singh SK, Mishra MK, Singh S, Singh R. Promising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer. Cancers. 2024;16(12):2205. doi:10.3390/cancers16122205

BibTeX
@article{Kaur2024,
  author = {Kaur, Prabhjot and Singh, Santosh Kumar and Mishra, Manoj K and Singh, Shailesh and Singh, Rajesh},
  title = {Promising Combinatorial Therapeutic Strategies against Non-Small Cell Lung Cancer},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {12},
  pages = {2205},
  doi = {10.3390/cancers16122205}
}
Kostenlos starten →